Ten years clinical experience with partial ileal bypass in management of the hyperlipidemias.
PDF (1.7M)
Journal: 1974/December - Annals of Surgery
ISSN: 0003-4932
PUBMED: 4416064
Abstract:
The first partial ileal bypass operation specifically for the reduction of plasma lipids was performed by us in 1963. Since then we have operated upon and followed for more than three months 126 hyperlipidemic patients. Clinical metabolic studies, before and after the procedure, have demonstrated a 60% decrease in cholesterol absorption, a 3.8-fold increase in total fecal steroid excretion, a 5.7-fold increase in cholesterol synthesis, a 3-fold increase in cholesterol turnover, and a one-third decrease in the miscible cholesterol pool. Circulating cholesterol levels have been lowered an average 41.1% from the preoperative but postdietary baseline. An average 53% cholesterol reduction has been achieved from a pretreatment baseline using a combination of dietary and surgical management. Plasma triglycerides have been reduced in primary hypertriglyceridemic patients (type IV) an average of 52.6% from their preoperative but postdietary baseline. One patient died in the hospital and there have been 13 late deaths over the past 10 years. Four cases of postoperative bowel obstruction required reoperation. Diarrhea following partial ileal bypass is, as a rule, transistory and not a significant problem. No appreciable weight loss results from partial ileal bypass, which is an obvious distinction from the results of the far more massive jejuno-ileal bypass procedure for obesity. We have not encountered hepatotoxic, lithogenic, or nephrolithiasis complications in our partial ileal bypass patients. Sixty-nine per cent of our patients with preoperative angina pectoris have postoperative improvement or total remission of this symptom complex. Serial appraisal of followup coronary arteriographic studies offers preliminary evidence for lesion regression. It is concluded that partial ileal bypass is the most effective means for lipid reduction available today; it is obligatory in its actions, safe, and associated with minimal side effects.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(8)
References
(33)
Diseases
(1)
Conditions
(3)
Drugs
(2)
Chemicals
(2)
Organisms
(1)
Anatomy
(2)
Similar articles
Articles by the same authors
Discussion board
Ann Surg 180(4): 384-392
PMID: 4416064

Ten Years Clinical Experience with Partial Ileal Bypass in Management of the Hyperlipidemias

Abstract

The first partial ileal bypass operation specifically for the reduction of plasma lipids was performed by us in 1963. Since then we have operated upon and followed for more than three months 126 hyperlipidemic patients. Clinical metabolic studies, before and after the procedure, have demonstrated a 60% decrease in cholesterol absorption, a 3.8-fold increase in total fecal steroid excretion, a 5.7-fold increase in cholesterol synthesis, a 3-fold increase in cholesterol turnover, and a one-third decrease in the miscible cholesterol pool. Circulating cholesterol levels have been lowered an average 41.1% from the preoperative but postdietary baseline. An average 53% cholesterol reduction has been achieved from a pretreatment baseline using a combination of dietary and surgical management. Plasma triglycerides have been reduced in primary hypertriglyceridemic patients (type IV) an average of 52.6% from their preoperative but postdietary baseline. One patient died in the hospital and there have been 13 late deaths over the past 10 years. Four cases of postoperative bowel obstruction required reoperation. Diarrhea following partial ileal bypass is, as a rule, transistory and not a significant problem. No appreciable weight loss results from partial ileal bypass, which is an obvious distinction from the results of the far more massive jejuno-ileal bypass procedure for obesity. We have not encountered hepatotoxic, lithogenic, or nephrolithiasis complications in our partial ileal bypass patients. Sixty-nine per cent of our patients with preoperative angina pectoris have postoperative improvement or total remission of this symptom complex. Serial appraisal of followup coronary arteriographic studies offers preliminary evidence for lesion regression. It is concluded that partial ileal bypass is the most effective means for lipid reduction available today; it is obligatory in its actions, safe, and associated with minimal side effects.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 384
384
icon of scanned page 385
385
icon of scanned page 386
386
icon of scanned page 387
387
icon of scanned page 388
388
icon of scanned page 389
389
icon of scanned page 390
390
icon of scanned page 391
391
icon of scanned page 392
392

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Balfour JF, Kim R. Homozygous type II hyperlipoproteinemia treatment. Partial ileal bypass in two children. JAMA. 1974 Mar 11;227(10):1145–1151. [PubMed] [Google Scholar]
  • Baltaxe HA, Amplatz K, Varco RL, Buchwald H. Coronary arteriography in hypercholesterolemic patients. Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):784–790. [PubMed] [Google Scholar]
  • Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43(6):891–915.[PMC free article] [PubMed] [Google Scholar]
  • BUCHWALD H, GEBHARD RL. EFFECT OF INTESTINAL BYPASS ON CHOLESTEROL ABSORPTION AND BLOOD LEVELS IN THE RABBIT. Am J Physiol. 1964 Sep;207:567–572. [PubMed] [Google Scholar]
  • Buchwald H, Moore RB, Lee GB, Baltaxe H, Amplatz K, Frantz ID, Varco RL. Five years experience with the use of partial ileal bypass in the treatment of hypercholesterolemia and atherosclerosis. Isr J Med Sci. 1969 Jul-Aug;5(4):760–765. [PubMed] [Google Scholar]
  • Buchwald H, Varco RL. Ileal bypass in patients with hypercholesterolemia and atherosclerosis. Preliminary report on therapeutic potential. JAMA. 1966 May 16;196(7):627–630. [PubMed] [Google Scholar]
  • Buchwald H, Varco RL. Partial ileal bypass for hypercholesterolemia and atherosclerosis. Surg Gynecol Obstet. 1967 Jun;124(6):1231–1238. [PubMed] [Google Scholar]
  • CHAPMAN JM, GOERKE LS, DIXON W, LOVELAND DB, PHILLIPS E. Measuring the risk of coronary heart disease in adult population groups. The clinical status of a population group in Los Angeles under observation for two to three years. Am J Public Health Nations Health. 1957 Apr;47(4 Pt 2):33–42.[PMC free article] [PubMed] [Google Scholar]
  • Clot JP, Rouffy J, Loeper J, Mercadier M. Dérivation iléale, thérapeutique chirurgicale des hypercholestérolémies pures majeures (à propos de deux observations) Chirurgie. 1971 Feb 13;97(1):57–63. [PubMed] [Google Scholar]
  • DAWBER TR, MOORE FE, MANN GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health. 1957 Apr;47(4 Pt 2):4–24.[PMC free article] [PubMed] [Google Scholar]
  • DOYLE JT, HESLIN AS, HILLEBOE HE, FORMEL PF, KORNS RF. A prospective study of degenerative cardiovascular disease in Albany: report of three years' experience. I. Ischemic heart disease. Am J Public Health Nations Health. 1957 Apr;47(4 Pt 2):25–32.[PMC free article] [PubMed] [Google Scholar]
  • Fallon HJ, Woods JW. Response of hyperlipoproteinemia to cholestyramine resin. JAMA. 1968 Jun 24;204(13):1161–1164. [PubMed] [Google Scholar]
  • Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967 Jan 19;276(3):148–contd. [PubMed] [Google Scholar]
  • Fritz SH, Walker WJ. Ileal bypass in the control of intractable hypercholesterolemia. Clinical evaluation and case report. Am Surg. 1966 Oct;32(10):691–694. [PubMed] [Google Scholar]
  • Goodman DS, Noble RP. Turnover of plasma cholesterol in man. J Clin Invest. 1968 Feb;47(2):231–241.[PMC free article] [PubMed] [Google Scholar]
  • Grundy SM. Treatment of hypercholesterolemia by interference with bile acid metabolism. Arch Intern Med. 1972 Oct;130(4):638–648. [PubMed] [Google Scholar]
  • Helsingen N, Jr, Rootwelt K. Partial ileal by-pass. Kirurgisk behandling av hyperkolesterolemi. Nord Med. 1969 Nov 6;82(45):1409–1415. [PubMed] [Google Scholar]
  • Hunninghake DB, Tucker DR, Azarnoff DL. Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation. 1969 May;39(5):675–683. [PubMed] [Google Scholar]
  • Jeffcoate TN, Miller J, Roos RF, Tindall VR. Puerperal thromboembolism in relation to the inhibition of lactation by oestrogen therapy. Br Med J. 1968 Oct 5;4(5622):19–25.[PMC free article] [PubMed] [Google Scholar]
  • Knight L, Scheibel R, Amplatz K, Varco RL, Buchwald H. Radiographic appraisal of the Minnesota partial ileal bypass study. Surg Forum. 1972;23(0):141–142. [PubMed] [Google Scholar]
  • Krasno LR, Kidera GJ. Clofibrate in coronary heart disease. Effect on morbidity and mortality. JAMA. 1972 Feb 14;219(7):845–851. [PubMed] [Google Scholar]
  • Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med. 1968 Oct 17;279(16):856–858. [PubMed] [Google Scholar]
  • Levy RI, Fredrickson DS. The current status of hypolipidemic drugs. Postgrad Med. 1970 Jan;47(1):130–136. [PubMed] [Google Scholar]
  • MATTHEWS CM. The theory of tracer experiments with 131I-labelled plasma proteins. Phys Med Biol. 1957 Jul;2(1):36–53. [PubMed] [Google Scholar]
  • Moore RB, Frantz ID, Jr, Buchwald H. Changes in cholesterol pool size, turnover rate, and fecal bile acid and sterol excretion after partial ileal bypass in hypercholesteremic patients. Surgery. 1969 Jan;65(1):98–108. [PubMed] [Google Scholar]
  • Nygaard K, Helsingen N, Rootwelt K. Adaptation of vitamin B12 absorption after ileal bypass. Scand J Gastroenterol. 1970;5(5):349–351. [PubMed] [Google Scholar]
  • RUSS EM, EDER HA, BARR DP. Influence of gonadal hormones on protein-lipid relationships in human plasma. Am J Med. 1955 Jul;19(1):4–24. [PubMed] [Google Scholar]
  • Södal G, Gjertsen KT, Schrumpf A. Surgical treatment of hypercholesterolemia. Acta Chir Scand. 1970;136(8):671–674. [PubMed] [Google Scholar]
  • STAMLER J, PICK R, KATZ LN, PICK A, KAPLAN BM, BERKSON DM, CENTURY D. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA. 1963 Feb 23;183:632–638. [PubMed] [Google Scholar]
  • Steinbach JH, Blackshear PL, Jr, Varco RL, Buchwald H. High blood cholesterol reduces in vitro blood oxygen delivery. J Surg Res. 1974 Feb;16(2):134–139. [PubMed] [Google Scholar]
  • STEINBERG D. Chemotherapeutic control of serum lipid levels. Trans N Y Acad Sci. 1962 Apr;24:704–723. [PubMed] [Google Scholar]
  • Strisower EH, Kradjian RM, Nichols AV, Coggiola E, Tsai J. Effect of ileal bypass on serum lipoproteins in essential hypercholesterolemia. J Atheroscler Res. 1968 May-Jun;8(3):525–534. [PubMed] [Google Scholar]
  • Buchwald H. The dumping syndrome and its treatment. A review and presentation of cases. Am J Surg. 1968 Jul;116(1):81–88. [PubMed] [Google Scholar]
Copyright notice
Abstract
The first partial ileal bypass operation specifically for the reduction of plasma lipids was performed by us in 1963. Since then we have operated upon and followed for more than three months 126 hyperlipidemic patients. Clinical metabolic studies, before and after the procedure, have demonstrated a 60% decrease in cholesterol absorption, a 3.8-fold increase in total fecal steroid excretion, a 5.7-fold increase in cholesterol synthesis, a 3-fold increase in cholesterol turnover, and a one-third decrease in the miscible cholesterol pool. Circulating cholesterol levels have been lowered an average 41.1% from the preoperative but postdietary baseline. An average 53% cholesterol reduction has been achieved from a pretreatment baseline using a combination of dietary and surgical management. Plasma triglycerides have been reduced in primary hypertriglyceridemic patients (type IV) an average of 52.6% from their preoperative but postdietary baseline. One patient died in the hospital and there have been 13 late deaths over the past 10 years. Four cases of postoperative bowel obstruction required reoperation. Diarrhea following partial ileal bypass is, as a rule, transistory and not a significant problem. No appreciable weight loss results from partial ileal bypass, which is an obvious distinction from the results of the far more massive jejuno-ileal bypass procedure for obesity. We have not encountered hepatotoxic, lithogenic, or nephrolithiasis complications in our partial ileal bypass patients. Sixty-nine per cent of our patients with preoperative angina pectoris have postoperative improvement or total remission of this symptom complex. Serial appraisal of followup coronary arteriographic studies offers preliminary evidence for lesion regression. It is concluded that partial ileal bypass is the most effective means for lipid reduction available today; it is obligatory in its actions, safe, and associated with minimal side effects.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.